San Francisco Bay Area biotech stories.
Monday, June 18, 2012
Genentech, AC Immune ink 2nd Alzheimer's drug deal
Inc. and Swiss biotech AC Immune SA will work together on a drug that targets a major suspect in Alzheimer’s disease
The deal, the second between South San Francisco-based Genentech and AC Immune, potentially could be worth about $418 million, the companies said Monday.
The worldwide license agreement and research collaboration centers on AC Immune’s anti-Tau antibodies as treatments for Alzheimer’s and other neurodegenerative diseases.
Share to Twitter
Share to Facebook
Share to Pinterest
Post a Comment
Post Comments (Atom)